antiviral news

China's medical products watchdog announced the inclusion of two more domestically developed COVID drugs into the country's medical insurance coverage on Wednesday, which means all of the country's domestically produced anti-COVID drugs, which have been approved, are now supported by government subsidies.

We are in the midst of 2023’s first reporting period and many of the world’s largest pharmaceutical companies have presented their figures for the full year 2022. A theme is that products related to the Covid-19 pandemic seem to have reached their peak sales and will face a significantly tougher market going forward. BioStock took a closer look at some of the reports.

– Pipeline reprioritization emphasizes NASH and COVID-19 assets, ALG-055009 and ALG-097558, plus key ongoing collaborations, including the Merck & Co. (MSD) programs in NASH –– Overall workforce reduction (attrition and reduction in force) of approximately 25% since beginning of January 2022 –

The drug, molnupiravir, works by introducing a flurry of mutations to the viral genome; this helps to clear infections. But a study1 of more than 13 million SARS-CoV-2 sequences has uncovered sequences that bear molnupiravir’s fingerprints. The study’s authors say the results suggest that molnupiravir treatment has sparked the evolution of viral lineages carrying numerous mutations that, in at least some cases, have the capacity to spread to other individuals.

BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:00 p.m. ET.

Researchers from Fundacao Oswaldo Cruz (Fiocruz) have evaluated kinetin (MB-905) as an antiviral against SARS-CoV-2.